NCT02110810View on ClinicalTrials.gov

Indomethacin Decreases Post-ERCP Pancreatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

March 31, 2015

Conditions
Post ERCP Acute Pancreatitis
Interventions
DRUG

Indomethacin

Indomethacin suppository of 100 mg immediately afterwards while still under sedation

DRUG

2.6-g suppository of glycerin

to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation

Trial Locations (1)

Unknown

Department of Gastrointestinal Endoscopy and Department of Gastroenterology of the Specialties Hospital of the Western Medical Center of the Mexican Institute of Social Security., Guadalajara

All Listed Sponsors
lead

Instituto Mexicano del Seguro Social

OTHER_GOV

NCT02110810 - Indomethacin Decreases Post-ERCP Pancreatitis | Biotech Hunter | Biotech Hunter